VC-backed AbCellera seeks up to C$500m from IPO: Reuters

Vancouver-based antibody developer AbCellera Biologics said it expects to raise up to C$500 million (US$391 million) in its initial public offering on Nasdaq, Reuters reported.

Vancouver, British Columbia-based antibody developer AbCellera Biologics said it expects to raise up to C$500 million (US$391 million) in its initial public offering on Nasdaq, Reuters reported. Reuters reported in September that AbCellera had hired investment banks for an IPO and could look to raise between US$200 million and US$300 million. The company earlier in 2020 secured US$105 million in a Series B financing led by OrbiMed and DCVC Bio.

Read the Reuters story here.